



Corporate Headquarters  
Hikma Pharmaceuticals USA Inc.  
246 Industrial Way West  
Eatontown, NJ 07724-2206

T 1.732.542.1191  
F 1.732.542.0940

VIA ELECTRONIC MAIL

Office of the Vermont Attorney General  
109 State Street  
Montpelier, Vermont 05609  
AGO.highcostprescriptiondrugs@vermont.gov

July 21, 2020

Dear Sir/Madam,

In compliance with 18 V.S.A. § 4637, Hikma Pharmaceuticals USA Inc. ("Hikma") hereby provides the Office of Attorney General with notice that Hikma has introduced new generic prescription drugs (the "Products") at a wholesale acquisition cost that is over the threshold set for a specialty drug under the Medicare Part D program. A schedule identifying such Products is set forth as Exhibit A. Additionally, Hikma has recently completed a self-audit and found instances where Products were unintentionally omitted from having been reported. This communication and the attached Exhibit A corrects those omissions.

Additionally, in compliance with 18 V.S.A. § 4637(c) as further refined by 18 V.S.A. § 4637 (d), Hikma hereby provides the following information which is in the public domain or publicly available:

- (1) A description of the marketing and Pricing plans used in the launch of the new drug in the United States and internationally;
  - a. *These drugs are generic products; therefore no marketing and pricing plans are available. These products are sold in the United States only.*
- (2) The estimated volume of patients who may be prescribed the drug;
  - a. *The estimated average number of patients per month is unknown to Hikma.*
- (3) Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval;
  - a. *Not applicable.*
- (4) The date and price of acquisition if the drug was not developed by the manufacturer;
  - a. *Hikma did not acquire these products.*

Finally, Hikma would like to confirm that: (i) the Office of the Attorney General has not yet provided a format for submissions under this section; and (ii) this notice is an appropriate means of submitting the required information.

Very truly yours,

*Heather S. Patrick*

Heather Skye Patrick  
Sr. Analyst, Legal Affairs

## EXHIBIT A

NDC	PRODUCT	DATE OF INTRO TO MARKET	WAC
00584-0248-22	Imatinib Mesylate Tablets 100mg	10/1/2018	\$1,114.15
00584-0249-22	Imatinib Mesylate Tablets 400mg	10/1/2018	\$1,368.26
0054-0527-25	Clobazam Tablets 20mg	10/22/2018	\$1,054.37
0054-0561-50	Clobazam Oral Suspension 2.5mg per mL	10/22/2018	\$830.97
0054-4859-29	Triazolam Tablets 0.25mg	10/25/2018	\$733.39
0143-9597-21	Abiraterone Acetate Tablets 250mg	11/21/2018	\$8,840.58
0143-9280-01	Mitomycin for Injection 40mg	1/14/2019	\$1,264.00
00054-0520-21	Bosentan 62.5mg	6/3/2019	\$6,281.07
00054-0521-21	Bosentan 125mg	6/3/2019	\$6,281.07
00054-0468-23	Tetrabenazine 12.5mg	6/27/2019	\$1,464.98
00054-0469-23	Tetrabenazine 25mg	6/27/2019	\$2,929.95